Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BT-001
- Development stage
- Phase 2
- Lead developer
- BioInvent International
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
**BT-001** is a genetically engineered, replication-competent oncolytic vaccinia virus developed by BioInvent and Transgene for injectable advanced solid tumors. Derived from Transgene's Invir.IO platform, it selectively replicates in tumor cells to promote tumor-cell lysis and is armed to locally express a Treg-depleting human anti-CTLA-4 IgG1 antibody and human GM-CSF. This design combines oncolysis, localized CTLA-4 checkpoint blockade, and cytokine-mediated immune activation while aiming to minimize systemic exposure to the anti-CTLA-4 payload. It has been studied by intratumoral administration alone and with pembrolizumab in NCT04725331. ([bioinvent.com](https://www.bioinvent.com/en/clinical-programs/our-programs/bt-001ctla-4gm-csf))
- Other names
- oral adalimumabadalimumab variant
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on BT-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BT-001.